AMGN Amgen, Inc.
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Company profile
Ticker
AMGN
Exchange
Website
CEO
Robert A. Bradway
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
Former names
AMGEN
SEC CIK
Corporate docs
IRS number
953540776
Calendar
1 May 20
4 Jun 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | 6.16B | 6.2B | 5.74B | 5.87B | |
| Net income | 1.83B | 1.7B | 1.97B | 2.18B | |
| Diluted EPS | 3.07 | 2.85 | 3.27 | 3.57 | |
| Net profit margin | 29.62% | 27.48% | 34.30% | 37.11% | |
| Operating income | 2.36B | 2.05B | 2.48B | 2.68B | |
| Net change in cash | 41M | 51M | -15M | -8M | |
| Cash on hand | 718M | 677M | 626M | 641M | |
| Cost of revenue | 1.51B | 1.25B | 1.04B | 1.01B |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | 23.36B | 23.75B | 22.85B | 22.99B | |
| Net income | 7.84B | 8.39B | 1.98B | 7.72B | |
| Diluted EPS | 12.88 | 12.62 | 2.69 | 10.24 | |
| Net profit margin | 33.57% | 35.35% | 8.66% | 33.59% | |
| Operating income | 9.67B | 10.26B | 9.97B | 9.79B | |
| Net change in cash | 97M | 71M | 51M | 52M | |
| Cash on hand | 677M | 580M | 509M | 458M | |
| Cost of revenue | 4.36B | 4.1B | 4.07B | 4.16B |
Financial data from Amgen earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|
| 20 May 20 | Ronald D Sugar | Common Stock | Sell | Dispose S | 229.27 | 1,000 | 229.27K | 15,482 |
| 20 May 20 | Ronald D Sugar | Common Stock | Option exercise | Aquire M | 54.69 | 1,000 | 54.69K | 16,482 |
| 20 May 20 | Ronald D Sugar | Nqso Common Stock | Option exercise | Dispose M | 54.69 | 1,000 | 54.69K | 8,000 |
| 5 May 20 | Austin Wanda M | Common Stock | Grant | Aquire A | 0 | 846 | 0 | 3,194 |
| 5 May 20 | Eckert Robert | Common Stock | Grant | Aquire A | 0 | 846 | 0 | 12,031 |
| 5 May 20 | Druker Brian | Common Stock | Grant | Aquire A | 0 | 846 | 0 | 2,719 |
| 5 May 20 | Garland Greg C. | Common Stock | Grant | Aquire A | 0 | 846 | 0 | 9,024 |
Institutional ownership Q1 2020
75.5% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 1958 |
| Opened positions | 100 |
| Closed positions | 195 |
| Increased positions | 763 |
| Reduced positions | 838 |
13F shares |
Current |
|---|---|
| Total value | 90.01B |
| Total shares | 444.39M |
| Total puts | 4.78M |
| Total calls | 4.97M |
| Total put/call ratio | 1.0 |
Largest owners |
Shares | Value |
|---|---|---|
| Vanguard | 49.65M | $10.06B |
| BLK BlackRock | 46.46M | $9.42B |
| Capital Research Global Investors | 33.11M | $6.71B |
| STT State Street | 26.21M | $5.31B |
| Primecap Management | 18.48M | $3.75B |
| FMR | 17.65M | $3.58B |
| Geode Capital Management | 10.12M | $2.05B |
| NTRS Northern Trust | 7.98M | $1.62B |
| BAC Bank of America | 7.8M | $1.58B |
| MS Morgan Stanley | 7.26M | $1.47B |
Financial report summary
?Competition
Scios • Poniard Pharmaceuticals • Imclone Systems • Ir Biosciences • Celgene • ImmunoCellular Therapeutics • Novelion Therapeutics • Spectrum Pharmaceuticals • Medimmune • GenaeraManagement Discussion
- * Change in excess of 100%.
- Future sales of our products will depend in part on the factors discussed below and in the following sections of our Annual Report on Form 10-K for the year ended December 31, 2019: (i) Item 1. Business—Marketing, Distribution and Selected Marketed Products, (ii) Item 1A. Risk Factors and (iii) Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview, and Results of Operations—Product Sales, as well as in our Quarterly Report on Form 10-Q for the period ended March 31, 2020, in Part II, Item 1A. Risk Factors.
- The slight increase in ENBREL sales for the three months ended March 31, 2020, was driven by favorable changes to estimated sales deductions and inventory, offset by lower unit demand and net selling price. For the remainder of 2020, we expect the trend of lower unit demand to continue.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
AABP, acknowledged, adalimumab, Adaptive, adult, advice, Aid, anniversary, Annora, antibody, antiresorptive, Arthrex, backlog, BeiGene, build, cancellation, capacity, celebrating, China, chronic, Cir, combat, compulsory, conclusion, confirmatory, construing, consultation, coordinated, customer, cybersecurity, deCODE, dedesignate, Defense, degree, diagnosed, diagnostic, disposable, dissemination, distancing, downturn, ease, elderly, enrolled, enrollment, equal, equally, ESA, essential, exacerbate, exceeded, Fed, flexibility, fluidity, globe, goal, griffith, Hetero, hospital, hypothetical, Icelandic, immunomodulatory, immunosuppressive, incident, inequitable, infection, influence, internationally, investee, Japanese, joining, Judge, KANJINTI, Keytruda, labor, legacy, low, Magistrate, magnitude, mandate, Markman, medical, minimize, mitigate, mitigation, modification, monetization, month, movement, MSP, MVASI, navigate, Nephew, NIVESTYMTM, outbreak, ownership, pandemic, passage, pause, paused, pediatric, peter, precipitate, premium, prepaid, presence, procurement, produce, prolonged, proportionate, protocol, rapid, reassessment, recession, redemption, regular, remanded, remanding, remeasurement, remote, remotely, renamed, repaid, representation, rescheduled, retaliatory, revert, satisfaction, scope, screening, shareholder, Singapore, size, slightly, Smith, sotorasib, spread, Stafford, stakeholder, Stivarga, strain, strategy, subset, suspended, suspending, Switzerland, temporarily, trajectory, transfer, transferred, transferring, transmission, travel, trend, turn, uncertain, uncertainty, unclean, unemployment, Unichem, unpaid, unpredictable, upcoming, venture, Vice, voting, wider, widespread, workforce, worsen
Removed:
AAA, abandoned, AbbVie, adjusted, ANDA, announced, antitrust, Apotex, application, applied, arising, asserted, assistance, Aventisub, borrowing, carry, cinacalcet, claim, classification, classified, commencement, commercially, component, composed, creating, defendant, denying, direct, disclose, discount, discretion, efficient, enforcement, enhance, estate, etelcalcetide, exclude, exercise, expired, failure, formulation, fund, FZE, impaired, implementation, implicit, incremental, indefinitely, inflation, innovation, invalid, invalidity, IPR, issue, Johnston, KANJINTITM, Kashiv, launch, lease, leasing, lifted, Lori, maintaining, marketing, molecule, mortgage, multiple, MVASITM, Mylan, network, noncancelable, noncurrent, nonlease, Northern, offer, ordered, package, Parsabiv, Pennsylvania, permitted, prepayment, prospective, protection, purported, putative, real, Regeneron, reinvest, renew, renewal, rental, repatriation, represent, repurchased, residual, resolved, responded, retained, revalue, reviewed, ROU, Sensipar, set, small, space, stay, stayed, sublease, Sun, terminate, therapy, undistributed, vacate, vehicle, Watson
Financial reports
10-Q
2020 Q1
Quarterly report
1 May 20
10-K/A
2019 FY
Annual report (amended)
13 Feb 20
10-K
2019 FY
Annual report
12 Feb 20
10-Q
2019 Q3
Quarterly report
30 Oct 19
10-Q
2019 Q2
Quarterly report
31 Jul 19
10-Q
2019 Q1
Quarterly report
1 May 19
10-K
2018 FY
Annual report
13 Feb 19
10-Q
2018 Q3
Quarterly report
31 Oct 18
10-Q
2018 Q2
Quarterly report
27 Jul 18
10-Q
2018 Q1
Quarterly report
25 Apr 18
Current reports
8-K
Submission of Matters to a Vote of Security Holders
20 May 20
8-K
Entry into a Material Definitive Agreement
6 May 20
8-K
Amgen Reports First Quarter 2020 Financial Results
30 Apr 20
8-K
Amgen Update RegardingCOVID-19 For Media
31 Mar 20
8-K
Entry into a Material Definitive Agreement
21 Feb 20
8-K
Amgen Reports Fourth Quarter and Full Year 2019 Financial Results
30 Jan 20
8-K/A
Financial Statements and Exhibits
27 Jan 20
8-K
Regulation FD Disclosure
2 Jan 20
8-K
Entry into a Material Definitive Agreement
12 Dec 19
8-K
Completion of Acquisition or Disposition of Assets
21 Nov 19
Registration and prospectus
424B2
Prospectus for primary offering
6 May 20
FWP
Free writing prospectus
5 May 20
424B3
Prospectus supplement
4 May 20
424B2
Prospectus for primary offering
20 Feb 20
FWP
Free writing prospectus
18 Feb 20
424B3
Prospectus supplement
18 Feb 20
S-3ASR
Automatic shelf registration
10 Feb 20
SC TO-I/A
Issuer tender offer statement (amended)
8 Mar 18
SC TO-I/A
Issuer tender offer statement (amended)
6 Mar 18
SC TO-I/A
Issuer tender offer statement (amended)
26 Feb 18
Proxies
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEFA14A
Additional proxy soliciting materials
29 Apr 20
PX14A6G
Letter to shareholders
15 Apr 20
DEFA14A
Additional proxy soliciting materials
13 Apr 20
DEFA14A
Additional proxy soliciting materials
7 Apr 20
DEF 14A
Definitive proxy
7 Apr 20
DEFA14A
Additional proxy soliciting materials
13 May 19
DEFA14A
Additional proxy soliciting materials
2 May 19
DEFA14A
Additional proxy soliciting materials
29 Apr 19
DEFA14A
Additional proxy soliciting materials
22 Apr 19
Other
CT ORDER
Confidential treatment order
24 Oct 19
CT ORDER
Confidential treatment order
3 Jun 19
CT ORDER
Confidential treatment order
30 May 18
CT ORDER
Confidential treatment order
17 May 18
CT ORDER
Confidential treatment order
4 Dec 17
CT ORDER
Confidential treatment order
8 Sep 17
CT ORDER
Confidential treatment order
15 Aug 17
CT ORDER
Confidential treatment order
26 May 17
CT ORDER
Confidential treatment order
8 May 17
CT ORDER
Confidential treatment order
6 Mar 17
Ownership
4
AMGEN / RONALD D SUGAR ownership change
21 May 20
4
AMGEN / Esteban Santos ownership change
8 May 20
4
AMGEN / DAVID M REESE ownership change
8 May 20
4
AMGEN / David Piacquad ownership change
8 May 20
4
AMGEN / Cynthia M Patton ownership change
8 May 20
4
AMGEN / Lori A Johnston ownership change
8 May 20
4
AMGEN / Peter H. Griffith ownership change
8 May 20
4
AMGEN / Jonathan P Graham ownership change
8 May 20
4
AMGEN / Murdo Gordon ownership change
8 May 20
4
AMGEN / Robert A Bradway ownership change
8 May 20
Patents
GRANT
Design
Autoinjector
2 Jun 20
Inventors: Margaux Frances Boyaval, Sigrid Moeslinger, Masamichi Udagawa
GRANT
Design
Autoinjector with removable cap
2 Jun 20
Inventors: Brian Stonecipher, Ferry Tamtoro, Ryan Jerome Ramos, Sigrid Moeslinger, Masamichi Udagawa, Gail Devan Hunter, Laurie Martin Burns
GRANT
Utility
Pyridine sulfonamides
2 Jun 20
Inventors: Matthew Weiss, John R. Butler, Benjamin Charles Milgram, Gwenaella Rescourio, Alessandro Boezio, Brian Andrew Sparling, Daniel La
GRANT
Utility
Pharmaceutical formulations
2 Jun 20
A method of stabilizing an aqueous protein or antibody formulation is disclosed herein.
APP
Utility
Electronic Drug Delivery Device
28 May 20
A drug delivery device includes a housing, a drug delivery assembly disposed within the housing along a longitudinal axis, and a cap defining a shell.